OverviewSuggest Edit

Spruce Biosciences is a biotechnology company developing therapies to serve patients with rare endocrine disorders. It offers a candidate for the treatment of congenital adrenal hyperplasia (CAH), which is a disorder that results in the inability to produce the critical stress hormone cortisol.
TypePublic
Founded2016
HQDaly City, CA, US
Websitesprucebiosciences.com

Latest Updates

Employees (est.) (Jun 2020)15
Share Price (Jan 2021)$20.9 (-2%)
Cybersecurity ratingAMore

Spruce Biosciences Office Locations

Spruce Biosciences has offices in Daly City and San Francisco
Daly City, CA, US (HQ)
2001 Junipero Serra Blvd #640
San Francisco, CA, US
1700 Montgomery St #212, San Francisco
Show all (2)

Spruce Biosciences Financials and Metrics

Spruce Biosciences Revenue

USD

Net income (H1, 2020)

(11.6m)

EBIT (H1, 2020)

(11.5m)

Market capitalization (21-Jan-2021)

485.9m

Closing stock price (21-Jan-2021)

20.9

Cash (30-Jun-2020)

36.6m

EV

453.8m
Spruce Biosciences's current market capitalization is $485.9 m.
Annual
USDFY, 2018FY, 2019

General and administrative expense

1.6m2.3m

R&D expense

8.4m10.8m

Operating expense total

10.0m13.1m

EBIT

(10.0m)(13.1m)
Half Year
USDH1, 2019H1, 2020

General and administrative expense

1.5m1.3m

R&D expense

5.9m10.3m

Operating expense total

7.4m11.5m

EBIT

(7.4m)(11.5m)
Annual
USDFY, 2018FY, 2019

Cash

4.1m3.9m

Prepaid Expenses

411.0k215.0k

Current Assets

4.8m4.7m

Total Assets

4.8m4.7m
Quarterly
USDQ2, 2020

Cash

36.6m

Prepaid Expenses

1.3m

Current Assets

38.5m

Total Assets

39.0m
Annual
USDFY, 2018FY, 2019

Net Income

(9.9m)(13.1m)

Depreciation and Amortization

1.0k12.0k

Accounts Payable

1.7m(226.0k)

Cash From Operating Activities

(8.6m)(12.6m)
Quarterly
USDQ2, 2019Q2, 2020

Net Income

(7.4m)(11.6m)

Depreciation and Amortization

1.0k18.0k

Accounts Payable

(747.0k)2.3m

Cash From Operating Activities

(8.4m)(10.7m)
USDFY, 2018

Financial Leverage

-0.3 x
Show all financial metrics

Spruce Biosciences Operating Metrics

Q2, 2020

Clinical Trials

6

Facility Space, sq. ft.

8.27 k
Show all operating metrics

Spruce Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

98/100

SecurityScorecard logo

Spruce Biosciences Online and Social Media Presence

Embed Graph

Spruce Biosciences News and Updates

Spruce Biosciences stock opens more than 20% above its IPO price, then pulls back

Shares of Spruce Biosciences Inc. rallied in their public debut, as they opened 21% above the initial public offering price. The stock's first trade was at $18.14 at 11:37 a.m. Eastern for 411,595 shares. The IPO was priced at $15 a share, in the middle of the expected range of $14 to $16 a share. …

Spruce Biosciences prices upsized IPO at $15 a share, to raise $90 million

Spruce Biosciences Inc. said Friday that its initial public offering, which was upsized by 20%, priced at $15 a share, as the California-based biopharmaceutical company developing treatments for endocrine disorders raised $90 million. The company said late Thursday that it sold 6.0 million shares i…

Spruce Biosciences Frequently Asked Questions

  • When was Spruce Biosciences founded?

    Spruce Biosciences was founded in 2016.

  • How many employees does Spruce Biosciences have?

    Spruce Biosciences has 15 employees.

  • Who are Spruce Biosciences competitors?

    Competitors of Spruce Biosciences include Biogen, MyoKardia and Otonomy.

  • Where is Spruce Biosciences headquarters?

    Spruce Biosciences headquarters is located at 2001 Junipero Serra Blvd #640, Daly City.

  • Where are Spruce Biosciences offices?

    Spruce Biosciences has offices in Daly City and San Francisco.

  • How many offices does Spruce Biosciences have?

    Spruce Biosciences has 2 offices.